IzidoreLossosMD

Hematology • Miami, FL

Professor of Hematology & Oncology, University Miami School of Medicine

Join to view full profile

Dr. Lossos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lossos' full profile

Already have an account?

Office
1611 NW 12th Ave
# M851
Miami, FL 33136
Phone+1 305-585-1111

Fax+1 305-243-9927

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1987

Certifications & Licensure

OR State Medical License 2002 - Present
FL State Medical License 2002 - 2026

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:South Florida Castle Connolly, 2012
Elected Member The American Society for Clinical Investigation, 2007
Join now to see all

Clinical Trials

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) Start of enrollment: 2007 Apr 24
Terminated
Phase 2
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma Start of enrollment: 2004 Apr 01
Completed
Phase 2
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma Start of enrollment: 2006 Feb 01
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2009 Mar 25
Active, not recruiting
Phase 2
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Start of enrollment: 2013 Mar 01
Completed
Phase 1
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 Start of enrollment: 2015 Nov 24
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE...
Paolo Strati, Richy Agajanian, Izidore S Lossos, Morton Coleman, Robert Kridel
British Journal of Haematology. 2024-12-12
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
Côme Bommier, Brian K Link, Brianna J Gysbers, Matthew J Maurer, Melissa C Larson
Blood Advances. 2024-12-10
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.
Juan Pablo Alderuccio, Alvaro J Alencar, Jonathan H Schatz, Russ A Kuker, Georgios Pongas
The Lancet. Haematology. 2024-12-06

Abstracts/Posters

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Omission of Staging Bone Marrow Biopsy Does Not Affect Outcomes in Patients with Stage I Extranodal Marginal Zone Lymphoma (EMZL) Treated with Radiation Therapy
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Splenic Marginal Zone Lymphoma: A U.S Population-Based Survival Analysis (1997-2016)
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Izidore S. Lossos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF-Κb Pathway
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Sylvester Cancer Tip Sheet for Dec. 2024December 17th, 2024
Zynlonta Pushing into Remission 2 Other Advanced Lymphomas: TrialsDecember 16th, 2024
ASH 2024: Antibody Shows Encouraging Results for Treating High-Risk Follicular Lymphoma and Marginal Zone LymphomaDecember 6th, 2024
Join now to see all